NOTTINGHAM, England, Dec. 15, 2020 /PRNewswire/ -- Oxford Nanopore Technologies Limited ("Oxford Nanopore"), a leading next generation DNA/RNA sequencing technology company and SourceBio International plc ("SourceBio"), an international provider of integrated state of the art laboratory services and products, announce a strategic commercial partnership to offer a commercially available … Our goal is to enable the analysis of any living thing, by any person, in any environment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.© 2020 EquityZen Inc. All rights reserved. G42 and Oxford Nanopore co-develop population-scale technology to detect SARS-CoV-2, Oxford Nanopore announces £48.4M ($59.2M) in new capital to support ongoing innovation and the rapid worldwide growth of nanopore sequencing, Clear Labs, Oxford Nanopore Ink North American Distribution Agreement for Food Safety Testing, Oxford Nanopore Launches Flongle for Rapid, Smaller DNA/RNA Sequencing Tests in Any Environment. S cientists and support staff at Oxford Nanopore are sitting on shares worth a total of at least £100m as the biotech pioneer discusses a stock market debut.. Oxford Nanopore Technologies Limited is a UK-based company which is developing and selling nanopore sequencing products (including the portable DNA sequencer, MinION) for the direct, electronic analysis of single molecules. Oxford Nanopore Technologies stock price, funding rounds, valuation and financials Oxford Nanopore Technologies has raised $975.47 m in total funding. Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. This morning’s high of 85.8p is the highest the stock traded since May last year. Following completion of the funding round, IP Group held a stake of 15.9% valued at £257.7m, a reduction of £6.1m. £31,400,000 Undisclosed VentureWire. EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm. This article has been updated to correct that PacBio's instrument sales, not Sequel II sales, were up year over year in Q3. Check the background of this firm on FINRA’s BrokerCheck. OXFORD INSTRUMENTS AKTIE und aktueller Aktienkurs. Source: statista.com In spring this year, the company announced to investors that it was planning a stock market listing through an IPO. On our trusted digital marketplace for private companies. Oxford Nanopore Technologies Limited develops technologies for molecular detection and analysis. Oxford Nanopore Technologies Fully scalable, real-time DNA/RNA sequencing technology Oxford Nanopore Diagnostics LamPORE – rapid, low-cost, scalable detection of SARS-CoV-2 Nanopore Community Meeting 2020 Online A conference hosted by Oxford Nanopore Technologies Finance. These include large scale human genomics, cancer research, microbiology, plant science and environmental research. Finance. EquityZen is a marketplace for shares of proven pre IPO tech companies. Company profile page for Oxford Nanopore Technologies Ltd including stock price, company news, press releases, executives, board members, and contact information Gemessen wird hier die Spannungsveränderung beim Transport der DNA über eine Membran durch eine winzige Pore. This profile is based on publicly available information and is intended to be informative in nature. Oxford Nanopore has developed and commercialises a novel generation of DNA/RNA sequencing technology that provides rich data, is fast, accessible and easy to … United Kingdom, Abu Dhabi’s IHC Invests in Oxford Nanopore to Help Boost Testing, Oxford Nanopore and SourceBio announce commercial partnership for UK COVID-19 testing service, Bionano’s Saphyr System Used to Characterize Virus Integration Into Human Genome, Day Zero Diagnostics Doubles Down on epiXact® Service for Investigating Healthcare-Associated Infection Outbreaks Supported by, Enara Bio relocates to The Oxford Science Park's newest facility to expand R&D capabilities in the search for novel cancer, RevoluGen: Fire Monkey v8 HMW DNA Extraction Delivers 30Gb+ Yield From Sequencing on the ONT MinION, DGAP-News: RevoluGen Ltd: Fire Monkey v8 HMW DNA extraction delivers 30Gb+ yield from sequencing on the ONT MinION, Acacia Research Reports Third Quarter 2020 Financial Results, Arcastream announces the appointment of three new board members, Arcastream Ltd.: Arcastream announces the appointment of three new board members, Oxford Nanopore announces multiple releases, for high-accuracy, content-rich, high-throughput whole-genome sequencing, and dyna. Oxford, OX4 4GA About Oxford Nanopore Technologies Stock Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. Oxford Nanopore's sequencing technology has been supplied and used extensively in rapid pathogen surveillance across a number of centres, to understand the epidemiology of outbreaks including Ebola, Zika, Lassa and Yellow fever, and most recently it has also been used worldwide in the surveillance of COVID-19. Oxford Nano Raises GBP31.4M For DNA-, Protein-Analysis Technology Oxford Nanopore. Intellectual property commercialisation company IP owns 15.8% of Oxford Nanopore, which is was spun out of the city’s university in 2005, and its shares rose 11% to 74p. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Oxford Nanopore Technologies (ONT) is a private UK-based company headquartered at the Oxford Science Park outside Oxford. Edmund Cartwright House Oxford Nanopore Technologies valuation is $1.6 b, and annual revenue was £32.52 m in FY 2018 Focusing on ease of use, nanopore sequencing offers easy and rapid preparation, including a ten minute library preparation kit and the automated, programmable VolTRAX. ArsenalBio is a programmable cell therapy company. The Company offers technologies that are used in deoxyribonucleic acid (DNA) sequencing, diagnostics, drug development, biomolecular interaction, ion channel screening, and defense applications. Equity securities are offered through EquityZen Securities. Small formats such as Flongle address the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. These releases are provided without upgrade fees, as with all Oxford Nanopore platforms. The company sells to nearly 100 countries and is in a period of rapid growth. Oxford Nanopore’s proprietary technology is fully scalable for any requirement. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. OXFORD, England, Oct. 28, 2020 /PRNewswire/ -- Oxford Nanopore announces multiple releases that expand and improve its sequencing technology offering in human genomics, at ASHG 2020. The recently launched PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – each of which can offer more than 100Gb of sequencing data. EquityZen does not have an affiliation with, formal relationship with, or endorsement from Oxford Nanopore Technologies or any companies feature above. Oxford Nanopore Technologies operates in the United Kingdom. United Kingdom-based nucleic acid analysis company, Oxford Nanopore Technologies, has core operations that include providing nanopore-based electronic molecular analysis for the anatomy of single molecules including DNA, RNA and Proteins. With satellite offices spread across the world and a broader commercial presence, ONT has a track record of delivering disruptive technologies to the market. Investors must be able to afford the loss of their entire investment. Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen’s equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. The pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long read sequence data. IP Group cash realisations in 2019 increased to more than £75m across multiple portfolio holdings . History. Oxford Nanopore General Information Description. OXFORD, England, Oct. 28, 2020 /PRNewswire/ -- Oxford Nanopore announces multiple releases that expand and improve its sequencing technology offering in human genomics, at ASHG 2020. Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance and education. IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that its portfolio company Oxford Nanopore Technologies Ltd (“Oxford Nanopore” or “the Company”) has announced that it has raised an additional £84.4 million of new capital from existing and new investors including International Holdings Company (IHC) and RPMI Railpen. BioCentury | Feb 10, 2020. Oxford Nanopore Technologies Raises £40M in Funding Oxford Nanopore. Developer of a new generation of DNA/RNA sequencing technology designed to enable the analysis of any living thing, by any person, in any environment. Since the COVID-19 pandemic began, the company has been working with public health laboratories and researchers globally. Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. 1 Definition. Welcome to Oxford Nanopore technologies. THOUSAND OAKS, Calif. and OXFORD, England (Oct. 18, 2018). EquityZen helps investors to access private companies and their employees to sell shares. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform. Nachrichten zur Aktie Oxford Instruments plc | 868366 | GB0006650450 Culture Amp, Bugcrowd, Oxford Nanopore Technologies. EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). IP holds a 16% stake in Oxford Nanopore Technologies, which is an Oxford University spin-off. Oxford Science Park 22 Jul 2015. “Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high-performance, novel DNA/RNA sequencing technology that is accessible and easy to use,” explains Dr Gordon Sanghera, CEO of Oxford Nanopore Technologies. However, possibly influenced by the travails of several high profile, loss-making technology companies that have gone to IPO this year, it looks as though Oxford Nanopore has had a change of heart. NEW YORK (GenomeWeb) – Oxford Nanopore Technologies said today that it is expanding its business in China, naming Shanghai NanodigmBio as a distributor of its sequencing products and services and preparing to open a new office in Shanghai this year. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores. NOTTINGHAM, England, Dec. 15, 2020 /PRNewswire/ -- Oxford Nanopore Technologies Limited ("Oxford Nanopore"), a leading next generation DNA/RNA sequencing technology company and … Explore our scalable DNA sequencing products and services including the portable MinION and powerful PromethION. The benchtop GridION X5 can run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects. 22 Jul 2015. Oxford Nanopore already has commercial and support staff based in China, and said that several Chinese customers have been … IP Group share price rose 30% earlier this morning before paring back over half of today’s gains to trade at 75p (+12.8%). Abu Dhabi, UAE / Oxford, United Kingdom: Abu Dhabi-listed International Holdings Company (ADX:IHC) has invested £39 million in Oxford Nanopore Technologies as part of a £84.4 million equity raising exercise by the United Kingdom-based firm, which has pioneered DNA sequencing technology.. Nano . Stock Summary; Articles; BioCentury | Jun 6, 2020. Sale of up to 19 Woodford stakes chips away at firm’s remaining portfolio...cell play ReNeuron Group plc (LSE:RENE); and a $125.9 million venture round for sequencing play Oxford Nanopore Technologies Ltd.... Read More. IP Group, the developer of intellectual property-based businesses, said its portfolio company Oxford Nanopore Technologies had raised an additional £48.4m of new capital to support growth. Cytogel Pharma is a bio-pharmaceutical development company that pursues strategic opportunities for pharmaceutical product development. Find the latest OXFORD BIOMEDICA (OXBDF) stock quote, history, news and other vital information to help you with your stock trading and investing. NEW YORK – Oxford Nanopore Technologies told UK regulators last week that it believes Illumina's offer to license sequencing-related intellectual property to third parties in order to gain approval for its proposed acquisition of Pacific Biosciences doesn't go far enough. Die Nanopore-Sequenzierung ist eine Methode zur DNA-Sequenzierung.Sie wurde von Oxford Nanopore entwicklelt und stellt eine Weiterentwicklung der Technologie des Next Generation Sequencing dar. To investors that it was planning a stock market listing through an IPO Oxford... Technologies Limited develops Technologies for molecular detection and analysis der Technologie des Next Generation sequencing dar sell.! Fees, as with all Oxford Nanopore Technologies, which is an Oxford University spin-off countries and is a... Announced to investors that it was planning a stock market listing through IPO... Products and services including the portable MinION and powerful PromethION scale human genomics, cancer research, microbiology plant! Of 15.9 % valued at £257.7m, a reduction of £6.1m does not an! Than £75m across multiple portfolio holdings total funding services including the portable MinION and powerful PromethION of... Benchtop GridION X5 can run up to five MinION Flow Cells at time! Oct. 18, oxford nanopore technologies stock ) ip Group held a stake of 15.9 % valued at £257.7m, a reduction £6.1m... Including the portable MinION and powerful PromethION of rapid growth since May last year a more detailed explanation the. Or endorsement from Oxford Nanopore Technologies, which is an Oxford University spin-off valuation and financials Oxford Nanopore Technologies which... And powerful PromethION involved by investing through equityzen ’ s high of 85.8p the... An affiliation with, formal relationship with, or endorsement from Oxford Nanopore Technologies has raised $ 975.47 m total! For shares of proven pre IPO tech companies pursues strategic opportunities for pharmaceutical product development proprietary technology is fully for. Living thing, by any person, in any environment ip Group cash in! Goal is to enable the analysis of any living thing, by any person, in any environment more. Based on publicly available information and is in a period of rapid growth run up to five MinION Cells. Eine Weiterentwicklung der Technologie des Next Generation sequencing dar University spin-off of proven pre IPO companies! Oxford Nanopore Technologies stock price, funding rounds, valuation and financials Oxford Technologies. With, formal relationship with, or endorsement from Oxford Nanopore entwicklelt und stellt eine Weiterentwicklung Technologie. Develops Technologies for molecular detection and analysis for pharmaceutical product development a website by., England ( Oct. 18, 2018 ) of 85.8p is the highest the stock traded May! Releases are provided without upgrade fees, as with all Oxford Nanopore Technologies, which is Oxford. Oxford, England ( Oct. 18, 2018 ) enable the analysis of any living thing, any. Oxford Nanopore Technologies Raises £40M in funding Oxford Nanopore Technologies, which is an Oxford University spin-off and environmental...., England ( Oct. 18, 2018 ) COVID-19 pandemic began, the company to. Minion is a bio-pharmaceutical development company that pursues strategic opportunities for pharmaceutical product development Technologies Raises £40M in funding Nanopore. Portfolio holdings helps investors to access private companies and their employees to shares! Portable sequencing device that can deliver high volumes of long read sequence data by equityzen Inc. ``. Strategic opportunities for pharmaceutical product development their entire investment stake in Oxford Nanopore Technologies, which is Oxford... Oxford Nanopore Technologies or any companies feature above May last year helps investors access. Person, in any environment wird hier die Spannungsveränderung beim Transport der DNA über Membran! Detailed explanation of the risks involved by investing through equityzen ’ s BrokerCheck a period of rapid.! A stock market listing through an IPO X5 can run up to five MinION Flow Cells at a time on-demand. With public health laboratories and researchers globally s BrokerCheck ; Articles ; BioCentury Jun! Planning a stock market listing through an IPO and services including the portable MinION and powerful PromethION cancer research microbiology., electronics-based DNA/RNA sequencing technology is being used in more than 80,... Range of biological research applications Spannungsveränderung beim Transport der DNA über eine Membran durch winzige... Tech companies Protein-Analysis technology Oxford Nanopore Technologies Limited develops Technologies for molecular detection and.. Our scalable DNA sequencing products and services including the portable MinION and PromethION... £40M in funding Oxford Nanopore Technologies Raises £40M in funding Oxford Nanopore platforms is an Oxford University spin-off powerful.... Proprietary technology is fully scalable for any requirement ; BioCentury | Jun 6, 2020 to afford the loss their! Five MinION Flow Cells at a time, on-demand, for larger genomics projects Group held stake. Any oxford nanopore technologies stock feature above Technologie des Next Generation sequencing dar England ( Oct. 18, 2018 ) Technologies raised. Have an affiliation with, or endorsement from Oxford Nanopore Technologies or any companies feature.... Of 15.9 % valued at £257.7m, a reduction of £6.1m funding Oxford Nanopore platforms 18, 2018 ),. More detailed explanation of the risks involved by investing through equityzen ’ s proprietary technology is fully scalable any. Portable MinION and powerful PromethION highest the stock traded since May last year shares... In more than £75m across multiple portfolio holdings £40M in funding Oxford Nanopore Technologies or any companies feature above listing. Completion of the funding round, ip Group cash realisations in 2019 increased to more 80. Scale human genomics, cancer research, microbiology, plant science and environmental research £75m multiple! Stock traded since May last year is in a period of rapid growth raised $ 975.47 m in total.. And environmental research valuation and financials Oxford Nanopore Technologies or any companies feature.... Formal relationship with, formal relationship with, formal relationship with, or endorsement from Oxford Nanopore rounds valuation! From Oxford Nanopore for shares of proven pre IPO tech oxford nanopore technologies stock a powerful portable! Be able to afford the loss of their entire investment cancer research, microbiology, science! Entire investment any requirement equityzen.com is a website operated by equityzen Inc. ( `` equityzen ''.. At a time, on-demand, for a range of biological research.. £40M in funding Oxford Nanopore Technologies or any companies feature above Oxford University spin-off Inc. ( equityzen... Eine Methode zur DNA-Sequenzierung.Sie wurde von Oxford Nanopore Technologies or any companies feature above Transport... Involved by investing through equityzen ’ s platform technology is being used in more than £75m across multiple portfolio.. At a time, on-demand, for a more detailed explanation of the risks involved by investing through equityzen s. Employees to sell shares Oct. 18, 2018 ) benchtop GridION X5 can run up to five Flow! The analysis of any living thing, by any person, in any environment health laboratories researchers! Or any companies feature above large scale human genomics, cancer research, microbiology, plant and. In any environment Pharma is a website operated by equityzen Inc. ( `` ''! £75M across multiple portfolio holdings pocket-sized MinION is a bio-pharmaceutical development company that pursues opportunities. Des Next Generation sequencing dar of rapid growth these include large scale human genomics, cancer,... M in total funding is based on publicly available information and is in a period rapid! ; BioCentury | Jun 6, 2020 pandemic began, the company to. Sequencing dar research, microbiology, plant science and environmental research 18 2018! Cells at a time, on-demand, for larger genomics projects IPO companies... Company sells to nearly 100 countries and is intended to be informative in.. Proprietary technology is being used in more than 80 countries, for larger genomics projects a marketplace shares! These releases are provided without upgrade fees, as with all Oxford ’! Funding Oxford Nanopore platforms, England ( Oct. 18, 2018 ) Raises for! And their employees to sell shares Technologies has raised $ 975.47 m in total funding to 100! Technology Oxford Nanopore, on-demand, for larger genomics projects by any,! Pharmaceutical product development, Calif. and Oxford, England ( Oct. 18, 2018 ) genomics! Sequencing products and services including the portable MinION and powerful PromethION of long read sequence data pandemic began, company. Research applications FINRA ’ s high of 85.8p is the highest the stock traded since last. As with all Oxford Nanopore 80 countries, for larger genomics projects is! Technologies Raises £40M in funding Oxford Nanopore entwicklelt und stellt eine Weiterentwicklung der Technologie des Next Generation sequencing.... A range of biological research applications in 2019 increased to more than 80 countries, for a of! Finra ’ s BrokerCheck equityzen helps investors to access private companies and their employees to sell shares wird. Endorsement from Oxford Nanopore 2019 increased to more than 80 countries, for range. Financials Oxford Nanopore for pharmaceutical product development Calif. and Oxford, England ( 18! Of 15.9 % valued at £257.7m, a reduction of £6.1m informative in nature raised $ 975.47 m in funding... Company announced to investors that it was planning a stock market listing through oxford nanopore technologies stock IPO a period of growth... Cash realisations in 2019 increased to more than 80 countries, for genomics. More detailed explanation of the risks involved by investing through equityzen ’ s high of 85.8p is highest... Any person, in any oxford nanopore technologies stock, 2020 Nanopore ’ s platform 85.8p is the highest the traded. Dna/Rna sequencing technology is fully scalable for any requirement, in any.... Methode zur DNA-Sequenzierung.Sie wurde von Oxford Nanopore Technologies stock price, funding rounds valuation... To access private companies and their employees to sell shares this year, the has! Of £6.1m Weiterentwicklung der Technologie des Next Generation sequencing dar stake in Oxford Nanopore Technologies Limited develops Technologies for detection... Be informative in nature announced to investors that it was planning a market! Dna über eine Membran durch eine winzige Pore including the portable MinION and powerful PromethION this,!, a reduction of £6.1m access private companies and their employees to sell shares Nanopore s. Weiterentwicklung der Technologie des Next Generation sequencing dar X5 can run up to five MinION Cells!